CYP2D6 rs5030866: Pharmacogenomics and *8 Variant
The genetic variant rs5030866 is a single-nucleotide polymorphism located in the CYP2D6 gene. It serves as the defining variant for the CYP2D6*8 haplotype, creating a premature stop codon that results in a completely nonfunctional enzyme. Individuals carrying this variant exhibit reduced or abolished capacity to metabolize medications cleared via the CYP2D6 pathway.
What each genotype means
Normal metabolic capacity
This genotype represents the presence of two functional copies of the CYP2D6 gene, consistent with the reference sequence. Individuals with this profile typically exhibit normal drug metabolism for medications processed by the CYP2D6 enzyme. Please consult with your clinician or pharmacist regarding any specific medication dosing or potential drug interactions.
This is the most common genotype observed across all global populations.
Reduced metabolic capacity
This genotype indicates that one copy of the CYP2D6 gene carries the rs5030866 variant, which is associated with the CYP2D6*8 allele. This variant introduces a premature stop codon, resulting in a non-functional enzyme from that specific gene copy. You should discuss this result with your healthcare provider, as it may influence how your body processes certain medications.
This genotype is rare, with the minor allele frequency for rs5030866 reported as less than 0.005 in European ancestry populations.
Absent metabolic capacity
This genotype indicates that both copies of the CYP2D6 gene carry the rs5030866 variant, which corresponds to the CYP2D6*8 allele. This leads to a complete loss of functional CYP2D6 enzyme activity, which may significantly impact the metabolism of drugs dependent on this pathway. It is essential to discuss this finding with your clinician or pharmacist to ensure appropriate medication management.
This genotype is extremely rare in the general population.
Genetic Architecture and the rs5030866 Variant
The rs5030866 variant is an exonic single-nucleotide substitution within the cytochrome P450 family 2 subfamily D member 6 (CYP2D6) gene, mapped to chromosome 22q13.2. Specifically annotated as c.505G>T (p.Gly169Ter or legacy G1758T), this mutation alters the coding sequence to introduce a premature termination codon. As a consequence, mRNA translation yields a truncated polypeptide lacking key catalytic domains, or the transcript undergoes nonsense-mediated decay. Within the standardized pharmacogene nomenclature curated by PharmVar, rs5030866 is the primary core marker defining the CYP2D6*8 star allele. Because the genetic variation directly prevents the synthesis of a functioning protein, it is classified functionally as a definitive null allele.
Biological Role of the CYP2D6 Enzyme
The CYP2D6 enzyme is an essential component of the hepatic cytochrome P450 monooxygenase system. Although accounting for only 2% to 4% of total hepatic CYP content, it contributes to the oxidative biotransformation and clearance of roughly 20% to 25% of all clinically prescribed medications. Its broad substrate catalog includes beta-blockers, antiarrhythmics, selective serotonin reuptake inhibitors, tricyclic antidepressants, typical and atypical antipsychotics, and certain opioids. In addition to eliminating drugs, CYP2D6 bioactivates prodrugs such as codeine and tramadol into their primary active analgesic metabolites, morphine and O-desmethyltramadol. Consequently, any alteration in CYP2D6 enzymatic capacity disrupts both medication clearance and active drug production.
Pharmacogenomic Evidence and Clinical Associations
Pharmacogenomic consortia, including the Clinical Pharmacogenetics Implementation Consortium (CPIC) and PharmGKB, assign the CYP2D6*8 allele an Activity Score of 0. When present alongside another nonfunctional allele (such as *3, *4, or *5), it establishes a Poor Metabolizer (PM) phenotype; when paired with a normal function allele (such as *1 or *2), it yields an Intermediate Metabolizer (IM) phenotype. Poor metabolizers clear standard substrates at severely reduced rates, elevating systemic drug concentrations and the hazard of dose-dependent adverse reactions, including tardive dyskinesia from antipsychotics or exaggerated cardiovascular effects from beta-blockers. Conversely, prodrugs fail to convert effectively, frequently leading to therapeutic failure. Because the allele is rare, statistical data from isolated single-variant prospective trials are limited, and recommendations are derived from pooled no-function allele models.
Frequency and Distribution Across Global Populations
The rs5030866 variant is considered rare worldwide. Reference genomic databases, including gnomAD and the CPIC global frequency repository, report that the minor T allele is identified almost exclusively at low frequencies in populations of European ancestry, generally falling below 0.5% (minor allele frequency < 0.005). In most East Asian, African, and Indigenous American demographic cohorts, the variant is exceptionally rare or practically absent. Because of its overall low prevalence, homozygous individuals (T/T) are seldom observed in population screenings, and the variant is usually detected as a heterozygous carrier state in broader multigene pharmacogenetic panels.
Clinical Utility and Next Steps for Patients
Understanding your rs5030866 genotype provides helpful insight into individual drug response traits, but it cannot be evaluated in isolation. A complete CYP2D6 metabolizer status requires comprehensive diplotype testing that accounts for both inherited alleles as well as structural copy number variations, such as full-gene deletions or duplications. Furthermore, nongenetic variables—including kidney and liver health, age, and drug-drug interactions involving CYP2D6 inhibitors—strongly dictate real-world metabolic clearance. Patients should never discontinue or modify prescribed medication dosages based on direct-to-consumer genetic findings. Any potential adjustments in therapeutic selection or dose titration must be reviewed directly with a licensed physician or clinical pharmacist.
How common is this variant?
The rs5030866 variant is rare across global populations, with a minor allele frequency typically below 0.005 (<0.5%) in individuals of European ancestry and virtually undetectable in most other ancestries.
Frequently asked questions
What is the relationship between rs5030866 and CYP2D6*8?
The rs5030866 variant is the defining genetic mutation for the CYP2D6*8 allele. It causes a nonsense mutation that terminates protein translation early, completely abolishing enzyme activity.
Does having rs5030866 mean my medications will not work?
Not necessarily. While this variant removes activity from one or both CYP2D6 gene copies, clinical outcomes depend on whether your medication relies on CYP2D6 for breakdown or activation, as well as the identity of your second allele.
How does this variant affect pain relievers like codeine?
Codeine requires functional CYP2D6 enzyme activity to convert into its active pain-relieving compound, morphine. Individuals who carry loss-of-function variants like *8 often experience inadequate pain relief from codeine or tramadol.
Can I adjust my drug doses if I test positive for rs5030866?
No, you should never alter your prescription regimens on your own based on genetic testing. Always discuss your pharmacogenomic test results with your prescribing doctor or pharmacist to determine whether standard monitoring or an alternative therapy is warranted.
Sources & further reading
Educational information only, last refreshed 9/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs5030866?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CYP2D6
This variant is a key marker for the CYP2D6*10 allele, which results in reduced enzymatic activity and altered metabolism of various psychiatric and analgesic medications.
This variant defines the CYP2D6*4 non-functional allele, which causes impaired metabolism of numerous clinically prescribed medications including antidepressants, tamoxifen, and codeine.
Defines the CYP2D6*17 allele (p.Thr107Ile), which exhibits reduced enzyme activity towards substrates like codeine and certain antidepressants.
Defines the CYP2D6*29 variant (p.Val338Met) conferring decreased metabolic capacity, primarily observed in populations of African descent.
Promoter variant defining the CYP2D6*41 allele, associated with reduced enzyme expression and decreased metabolic capacity for various drugs.
Defines the non-functional CYP2D6*41 splice defect associated with intermediate metabolizer phenotype affecting codeine, tamoxifen, and SSRI metabolism.